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Introduction
Cell death is a necessary and natural process that occurs 
under both physiological and pathological conditions in 
all tissues. Th  is process is also a critical mechanism in 
immune tolerance and in contraction of normal immune 
responses to exogenous antigens. Apoptosis is the pre-
dominant pathway for cell death, but cells can also under  go 
death through necrosis and necroptosis, a programmed 
cell death independent of caspase activation [1]. Apop-
totic cells must be quickly removed from tissues so that 
they elicit neither inﬂ  ammation nor immune responses. 
Ineﬃ   cient clearance of apoptotic cells and subsequent 
accumulation of apoptotic cell debris provoke a chronic 
inﬂ  ammatory response and may lead to breakdown of 
self-tolerance [2].
Autoimmunity in systemic lupus erythematosus (SLE) 
is believed to be driven by autoantigens. Certain key 
autoantigens are demonstrable on blebs of apoptotic 
cells. Considerable evidence supports the notion that SLE 
autoimmunity could be related to impaired or delayed 
clearance of apoptotic cells. Persistent apoptotic cells 
may progress to secondary necrotic cell death, a process 
associated with danger signals, accessible modiﬁ  ed 
autoantigens, and initiation of autoimmune reactions.
Clearance of apoptotic cells
Eﬃ     cient recognition and clearance of apoptotic cells 
involve many ligands, receptors, and bridging molecules 
between dying cells and phagocytes. In vitro studies have 
indicated that this process is tightly controlled and 
remarkably complex.
Early apoptotic cells express eat-me signals through 
asymmetric distribution of aminophospholipids such as 
phosphatidylserine (PS), phosphatidylethanolamine, and 
phosphatidylcholine to the outer leaﬂ  et. PS is the best-
characterized eat-me signal, and externalization of PS 
alone is eﬃ   cient enough to initiate the engulfment of 
apoptotic cells by macrophages (Mφs) [3]. In addition, 
apoptotic cells actively secrete chemoattractant factors 
known as ﬁ  nd-me signals to the environment to attract 
phagocytes, such as Mφs and dendritic cells (DCs). Th  e 
covalent dimer of ribosomal protein S19 was the ﬁ  rst 
identiﬁ  ed ﬁ  nd-me signal of apoptotic cells [4], but its 
mechanism of action is still unclear. Apoptotic thymo-
cytes release nucleotides (ATP and UTP) in a caspase-
dependent manner to attract monocytes [5], so that 
release of nucleotides can be blocked by the caspase 
inhibitor zVAD-fmk. A diverse ﬁ  nd-me signal has been 
identiﬁ  ed and is reviewed elsewhere [6]. Interestingly, a 
recent study reported that the 75 to 80 kDa iron-binding 
protein lactoferrin could serve as an anti-attraction 
(keep-out) signal by diﬀ   erent apoptotic cell lines. 
Lactoferrin mediates strong inhibition of neutrophil 
migration but not Mφ migration [7]. SIRP-α, another 
keep-out signal, was reported by Tsai and Discher [8]. 
CD47-SIRP-α signaling negatively regulates phagocytosis 
through inhibition of the downstream signaling events of 
phagocytic receptors. Loss of function or blocking of 
either molecule causes removal of viable cells that are not 
normally phagocytosed [9].
Recognition and binding of ﬁ   nd-me signals on the 
apoptotic cells initiate the engulfment of apoptotic cells. 
Receptors such as CD36, scavenger receptor A, and PS 
receptor can directly bind to the eat-me molecules and 
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help of bridging molecules (reviewed in [10,11]). Tyro-3, 
Axl, and Mertk (TAM) receptor tyrosine kinases bind to 
apoptotic cells with the aid of two vitamin K-dependent 
factors, growth arrest speciﬁ  c protein 6 and protein S 
[12,13]. Mice lacking Mertk have impaired clearance of 
apoptotic cells and develop lupus-like autoimmunity, 
while TAM triple-knockout mice suﬀ  er from more severe 
disease [14,15]. Th  ese mice develop a systemic auto-
immune disorder with swollen joints and footpads, skin 
lesions, and glomerular immune complex deposition. A 
broad spectrum of autoantibodies is detectable in the 
serum. TAM receptor signaling normally not only 
facilitates apoptotic clearance, but also downregulates 
proinﬂ   ammatory Mφs and DCs. Activation of TAM 
receptor signals leads to a broad inhibition of Toll-like 
receptor (TLR)-induced cytokines through the IFNAR-
STAT1 cassette to induce TLR suppressors SOCS1 and 
SOCS3 [16].
Defective clearance of apoptotic cells can result in 
accumulation of apoptotic debris. In the thymus and 
bone marrow, most developing T cells and B cells under-
go apoptosis due to failure of positive and negative selec-
tion. Th   ose apoptotic cells have to be cleared eﬃ   ciently in 
a non-inﬂ  ammatory way. Tisch and colleagues demon-
strated a key role of Mertk on T-cell central tolerance by 
enhancing negative selection of autoreactive T cells 
speciﬁ   c for pancreatic β cells [17]. Nonobese diabetic 
mice lacking Mertk failed to develop diabetes due to an 
increased thymic negative selection of β-cell-speciﬁ  c 
T  cells and an increased capacity of DCs to induce 
thymocyte apoptosis [17].
In germinal centers, clonal selection of high-aﬃ   nity 
B cells results in large numbers of apoptotic cells, includ-
ing autoreactive cells. Clearance of these cells is essential 
to maintain peripheral tolerance. Specialized phagocytes 
that clear dying cells are referred to as tingible body 
macrophages (TBMφs) in the germinal center. Nagata’s 
group revealed a critical role of milk fat globule epidermal 
growth factor 8 (MFG-E8) in integrin-mediated TBMφ 
phagocytosis of apoptotic cells [18]. MFG-E8 promotes 
the phagocytosis of apoptotic cells by serving as a 
bridging molecule between apoptotic cells and phago-
cytes. Without MFG-E8, mice developed autoimmune 
disease associated with defective apoptotic cell clear-
ance in the germinal center. Alternatively, when apop-
totic cell clearance was disturbed with MFG-E8 mutant 
protein D89E, autoantibodies against phospholipids and 
nuclear proteins were induced in mice [19]. Later, the 
same group reported a reduced level of MFG-E8 in 
some childhood-onset and adult SLE patients and a dose-
dependent inhibition of Mφ uptake of apoptotic cells by 
human MFG-E8 [20]. Aberrant splicing of MFG-E8 was 
also reported in SLE patients. Repeated administration of 
the same mutant MFG-E8 into mice induced anti-
cardiolipin and antinuclear autoantibodies [21]. Similarly, 
we discovered a primary role of Mertk on TBMφ 
clearance of apoptotic B cells in the germinal center. 
Large numbers of apoptotic bodies accumulated outside 
TBMφs in Mertk–/– mice immunized with NP-chicken γ-
globulin [22].
Th  e T-cell immunoglobulin mucin (TIM) gene family 
has recently been shown crucial for clearance of 
apoptotic cells, autoimmune regulation, and tolerance 
induction. Tim-1 and Tim-4 speciﬁ  cally bound PS on the 
surface of apoptotic cells [23]. Tim-4–/– mice show defects 
in apoptotic cell clearance by peritoneal Mφs and B-1 
cells. Tim-4–/– mice develop autoantibodies against 
dsDNA associated with hyperreactive T cells and B cells 
[24]. Tim-3, on the other hand, recognizes apoptotic cells 
via the FG loop in the IgV domain. Inhibition of apoptotic 
cell engulfment by CD8+ DCs through anti-Tim-3 mAb 
results in reduced autoantigen cross-presentation in vivo 
and in vitro. Administration of Tim-3 and Tim-4 mAb 
induces autoantibody production in animals [25].
Danger signals from later apoptotic cells/necrotic 
cells
Phagocytic clearance of apoptotic cells can inﬂ  uence 
immune responses dramatically by enhancing or suppres-
sing inﬂ  ammation,  depending on additional immune 
stimuli (Figure 1). DCs may present self-derived antigen 
if appropriate danger signals are provided. Defective or 
prolonged clearance of apoptotic cells allows them to 
progress to secondary necrosis, a stage where danger 
signals may accumulate. Our knowledge about danger 
signals released from apoptotic cells, however, is rather 
limited. Nucleic acid, proteins, inﬂ  ammatory cytokines, 
and metabolic intermediates are all well-accepted danger 
signals in other contexts [26]. We highlight recently 
described key danger signals in the present review.
High mobility group box 1 protein
High mobility group box 1 (HMGB1) is an evolutionary 
conserved ubiquitously expressed chromosomal protein 
consisting of two positively charged DNA binding 
domains, called HMG boxes A and B.
HMGB1 binds to and helps to stabilize dsDNA, 
ssDNA, distorted DNA, and nucleosomes. HMGB1 can 
be actively secreted from living cells and passively 
secreted from dying cells during late apoptosis and 
necrosis (reviewed in [27]). HMGB1 released from apop-
totic cells undergoes post-translational oxidative modiﬁ  -
ca  tion and acts as a proinﬂ   ammatory mediator [28]. 
HMGB1 has been found to be elevated signiﬁ  cantly in 
sera from lupus patients [28]. Th   e precise patho-
physiological role of HMGB1 in lupus, however, remains 
to be further elucidated. In UV-induced skin lesions of 
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coincident with clinical activity [29,30]. HMGB1 can 
interfere with apoptotic clearance by blocking cell surface 
PS, causing accumulation of apoptotic cells and worsen-
ing disease. HMGB1 can also increase production of 
IFNα by plasmacytoid DCs through TLR9 and RAGE, or 
of cytokines from activated B cells through TLR2. 
HMGB1 has been identiﬁ  ed as an autoantigen in lupus 
patients, and thus may itself be a target in autoimmune 
responses. Anti-HMGB1 autoantibodies are positively 
correlated with the SLE disease activity index [31]. 
Patients shown to have positive autoantibodies for 
HMGB1 presented with signiﬁ  cantly higher SLE disease 
activity index values.
Microparticles
Microparticles (MPs), also known as plasma membrane-
derived vesicles, are small membrane-bound vesicles 
released from dying cells via blebbing and shedding. MPs 
incorporate cytoplasmic proteins such as cytokines, 
growth factors, acute phase proteins, and DNA and RNA.
Increased numbers of plasma MPs have been docu-
mented in SLE patients with secondary anti-phos  pholipid 
syndrome [32,33]. Pisetsky and Lipsky proposed an 
autoadjuvant model for MPs as a revised version of the 
waste disposal hypothesis of SLE [34]. In this model, 
nucleic-acid-containing MPs act as autoadjuvants in both 
central tolerance and peripheral B-cell activation in 
normal individuals. MPs loaded with DNA and RNA 
enhance their stimulatory capacity and ensure eﬀ  ective 
central deletion during B-cell development. In individuals 
with SLE, MP may particularly promote the survival of 
DNA-speciﬁ  c and RNA-speciﬁ  c autoreactive B cells due to 
their eﬀ   ectiveness in stimulating B cells through their 
immunoglobulin receptors. Recently, Antwi-Baﬀ  our and 
colleagues revealed a dose-dependent competition of MPs 
with apoptotic cells for PS receptor on Mφs [35]. Th  e  fact 
that MPs express high concentrations of PS on their outer 
leaﬂ  et makes them potent inhibitors of phagocytosis of 
normal apoptotic cells. Th  is may result in secondary 
necrosis and subsequent increase of apoptotic debris.
To our knowledge, there is no universally accepted 
deﬁ  nition for MPs. A wide range of MP sizes (0.02 to 
2  μm) has been reported by diﬀ   erent groups in the 
literature [34,36]. MPs bear many surface adhesion 
molecules, making them likely to adhere to leukocytes or 
endothelial cells. Th  is and other physical characteristics 
of MPs add to diﬃ   culties in their quantitative analysis, 
emphasizing the need for attention to collecting, 
processing, and storage of samples containing MPs. Flow 
cytometry-based assays are routinely used in the ﬁ  eld, 
while electron or confocal microscopy may be better for 
Figure 1. Distinct balance of apoptotic cell clearance. Normal clearance of apoptotic cells (left side, blue) involves sequential signals and plays 
an important role in tolerance induction and maintenance. Infl  ammatory clearance of apoptotic cells (right side, red) involves multi-infl  ammatory 
stimuli, breaks down tolerance, and drives autoimmunity including systemic lupus erythematosus. Blue blebs: early apoptotic cells modify surface 
markers and release signals to regulate chemotaxis and phagocytosis. Red blebs: later apoptotic cells and necrotic cells lose the cell membrane 
integrity, leading to the release of danger signals and modifi  ed autoantigens. dRP S19, dimer of ribosomal protein S19; HMGB1, high mobility group 
box 1; IL, interleukin; LTF, lactoferrin; MP, microparticle; NET, neutrophil extracellular trap; PC, phosphatidylcholine; PE, phosphatidylethanolamine; 
PS, phosphatidylserine; TGF-β, transforming growth factor beta.
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[36]. An ELISA-based assay was also developed for 
platelet-derived MPs by Osumi and colleagues [37].
Neutrophil extracellular traps
Neutrophil extracellular traps (NETs), extended chroma-
tin networks released from activated neutrophils, con-
stitute an intricate mechanism used by neutrophils to 
capture and kill invading microorganisms [38]. In SLE 
patients, neutrophils are activated and express genes 
induced by type I interferons [39,40]. SLE patients pro-
duce antibodies against NETs and against neutrophil 
proteins such as myeloperoxidase and proteinase-3 [41]. 
Impaired recognition and clearance of apoptotic neutro-
phils may due to reduced expression of CD44 on neutro-
phils in SLE [42]. NETs are made of DNA, histones, and 
neutrophil proteins. Timely removal of NETs is essential 
to avoid self-antigen presentation. Zychlinsky and 
colleagues found that impaired degrada  tion of NETs in 
SLE patients correlates with lupus nephritis. Diﬃ   culty in 
NET clearance is due to the presence of DNase 1 
inhibitors and prevention of DNase 1 access to NETs by 
anti-NET antibodies [39].
DNase I
DNase I facilitates chromatin breakdown during apop-
tosis and has been implicated in the pathophysiology of 
SLE since the 1950s. Lupus-prone NZB/NZW mice have 
signiﬁ   cantly lower serum and urine concentrations of 
DNase I compared with normal mice [43], which may 
allow more immune complexes to persist in the kidney 
and further promote disease progression. An elegant 
study with the same model showed that reduced levels of 
renal DNase I coincided with deﬁ  cient fragmentation of 
chromatin from dead cells, implying that the lack of this 
enzyme may have caused delayed clearance [44]. Further-
more, DNase-I-deﬁ   cient mice developed a SLE-like 
syndrome with antinuclear antibodies, immune complex 
deposition, and glomerulonephritis [45]. Consistent with 
these ﬁ  ndings, lower serum DNase I activity was demon-
strated in SLE patients compared with patients with 
rheumatoid arthritis and scleroderma and compared 
with healthy controls [45,46]. In this regard, two DNase-
I-deﬁ  cient SLE patients with high serum titers of anti-
dsDNA antibodies were reported [47]. Attempts to use 
DNase I as a therapeutic agent in SLE were carried out by 
several groups and were mildly encouraging [48,49].
Disturbed apoptotic cell clearance in SLE patients
Much of the preceding evidence for apoptotic clearance 
impairment in SLE comes from mouse models of lupus. 
In human lupus, apoptotic cell bodies unengulfed by 
lymph node TBMφs have been observed in vivo. Free 
apoptotic debris found attached to follicular DCs might 
provide survival signals to autoreactive B cells generated 
from random somatic hypermutation [50]. Signiﬁ  cantly 
increased numbers of circulating endothelial cells in SLE 
patients have been interpreted to reﬂ   ect an enhanced 
apoptotic rate, and possibly decreased clearance of these 
cells [51]. Freshly isolated or cultured lymphocytes from 
SLE patients showed a signiﬁ  cantly increased fraction of 
cells undergoing apoptosis in comparison with normal 
control individuals or rheumatoid arthritis patients, with 
a correlation between SLE disease activity and the rate of 
in vitro apoptosis. Extracellular nucleosomes were also 
increased in proportion to the rate of apoptosis [52]. In 
juvenile-onset SLE, neutrophil apoptosis is signiﬁ  cantly 
increased, and this is thought to be due to an imbalance 
in proapoptotic and antiapoptotic factors in both 
neutrophils and sera from the patients [53].
UVB has long been associated with apoptosis induction 
and lupus ﬂ   ares. Caricchio and colleagues revealed a 
dose-dependent immunological fate of UVB-induced 
apoptosis: non-inﬂ   ammatory apoptosis from low-dose 
UVB, and proinﬂ  ammatory apoptosis from higher-dose 
UVB [54]. Later, Reefman and colleagues compared the 
apoptotic/necrotic rate of 14 SLE patients with 16 
controls in response to 200 MJ/cm2 UVB irradiation. 
Although sensitivity of SLE to UVB was not related to the 
numbers of apoptotic or necrotic keratinocytes in the 
skin [55], UVB-induced skin lesions were associated with 
apoptotic keratinocytes [56]. In another study, Fas-medi-
ated apoptosis was thought to account for the low numbers 
of bone marrow CD43+ cells in active SLE, although 
relatively small numbers of patients were studied [57].
An in vitro defect in apoptotic cell clearance has been 
described in SLE. Mφs cultured from SLE patients 
display morphological abnormalities with impaired 
phagocytosis of apoptotic cells [50,58]. Mφs derived from 
SLE monocytes or stem cells were smaller with less 
ability to diﬀ  erentiate and with impaired adhesion [58]. 
Moreover, sera from SLE patients possessed an enhanced 
capacity to induce apoptosis [59]. In this study, sera from 
37 sex-matched and age-matched SLE patients and a 
total of 37 other autoimmune/infectious disease and 
healthy donors were sampled; the apoptosis-inducing 
eﬀ  ect of the sera on normal monocytes or lymphocytes 
was compared. Th   e apoptosis-inducing eﬀ  ect was signi  ﬁ  -
cantly higher in sera from SLE patients than controls. 
Subsequent studies showed that the SLE sera-induced 
apoptosis is caspase dependent but death receptor 
independent [60]. Although the apoptosis-inducing 
factor has not yet been identiﬁ  ed, the existence of these 
factors may give rise to apoptotic cells in SLE and worsen 
the pathogenic condition. Interestingly, Dransﬁ  eld  and 
colleagues found that glucocorticoid-treated Mφs have 
increased capacity to phagocyte apoptotic neutrophils, 
apparently due to enhanced protein S signaling of the 
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of protein S in certain subsets of SLE patients [62]. 
Together, the data may support an important role of 
Mertk in the ineﬃ   cient clearance of apoptotic cells in 
certain SLE patients. A follow-up investigation of levels 
of TAM receptors in SLE patients may help in under-
standing the distinct role of TAM receptors in the patho-
genesis of SLE.
Th  ere are strong links between apoptotic clearance 
deﬁ  ciency and SLE, yet no direct etiological role has been 
established for impairment of apoptotic clearance in 
human SLE. Th  e initiating phase of SLE may be multi-
factorial and individually variable, while the presence of 
excessive apoptotic debris may have profound pathogenic 
relevance and correlation with disease activity. It has 
been shown that the presence of antinuclear antibodies, 
reactive with apoptotic debris, may render apoptotic cells 
proinﬂ  ammatory and thus create a vicious cycle produc-
ing further autoantibodies and inﬂ  ammation [63]. In this 
regard, the lupus erythematosus cell exempliﬁ  es  this 
phenomenon of phagocytosis of autoantibody-coated 
apoptotic cells. Lupus erythematosus cells were dis-
covered over 60 years ago, and the LE prep, where lupus 
white blood cells are observed to undergo spontaneous 
phagocytosis of debris in vitro, was the standard test for 
lupus until about 30 years ago [64].
Conclusions
Clearance of apoptotic cells is a daunting challenge to the 
immune system, which has multiple redundant receptor–
ligand systems to eﬃ     ciently eliminate senescent and 
superﬂ  uous apoptotic cells. It is now well established in 
animal models that this process may fall short under 
certain circumstances, leading to abnormally persistent 
and potentially immunogenic apoptotic and necrotic cells. 
Both in vivo and in vitro evidence supports the notion that 
certain human autoimmune diseases, particu  larly SLE, 
may also arise from impaired apoptotic cell clearance. 
Better understanding of the immuno  biology of apoptotic 
cell clearance may lead to new therapeutic approaches to 
lupus and related autoimmune diseases.
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